Home › New Findings Show Anti-Tumor Activity of KEYTRUDA (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
 

Keywords :   


New Findings Show Anti-Tumor Activity of KEYTRUDA (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma

2015-09-26 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent in Previously-Treated Patients Results from KEYNOTE-028 Presented at 2015 European Cancer Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) a type of head and neck cancer whose tumors express PD-L1 (1% of cells in tumor nests or PD-L1+ bands in stroma). Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558An Phan, (908) 255-6325orInvestor:Justin Holko, (908) 740-1879Teri Loxam, (908) 740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: show advanced activity patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.06Potential Tropical Cyclone One Graphics
18.06Summary for Potential Tropical Cyclone One (AT1/AL012024)
18.06Potential Tropical Cyclone One Forecast Advisory Number 5
18.06Nvidia becomes world's most valuable company
18.06CEO Spotlight: Catching Up with Ron Mittelstaedt of Waste Connections
18.06KDV Label names Gary Morrison SVP sales and marketing
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Public Advisory Number 4A
More »